Table 2.

Incidence of primary and secondary outcomes

Outcome per Time
(yr)Cumulative Incidence for Total Cohort (95% CI) (n=254) Cumulative Incidence for Supportive Therapy Group (95% CI) (n=130)Cumulative Incidence for Immunosuppressive Therapy Group (95% CI) (n=124)
Renal replacement therapy
 10 (NA)0 (NA)0 (NA)
 31 (0–4)1 (0–4)2 (0–6)
 53 (1–5)1 (0–4)4 (1–9)
 103 (1–7)1 (0–4)6 (2–12)
Mortality
 10 (0–2)0 (NA)1 (0–4)
 33 (1–6)1 (0–5)5 (2–11)
 56 (3–10)4 (1–11)8 (4–14)
 1010 (5–17)4 (1–11)15 (7–25)
Combined
 10 (0–3)0 (NA)1 (0–6)
 35 (2–8)2 (0–7)7 (4–14)
 58 (5–14)5 (2–13)12 (7–20)
 1014 (8–22)5 (2–13)20 (12–33)
Serum creatinine >265 μmol/L
 13 (2–6)0 (NA)7 (3–13)
 37 (4–11)2 (0–7)12 (7–19)
 510 (7–16)4 (2–12)16 (10–25)
 1016 (10–24)13 (5–31)20 (13–30)
Partial remission
 139 (33–45)41 (32–50)37 (28–45)
 370 (64–76)69 (60–76)72 (63–79)
 583 (77–87)84 (75–90)82 (74–88)
 1090 (85–94)90 (81–95)88 (80–93)
Complete remission
 15 (2–8)6 (3–11)3 (1–8)
 324 (19–30)28 (20–37)20 (13–28)
 538 (31–45)42 (32–52)34 (25–44)
 1052 (44–60)60 (46–72)45 (34–56)
Relapse
 113 (9–19)12 (7–21)14 (8–23)
 319 (14–26)14 (8–23)24 (16–35)
 527 (20–36)14 (8–23)39 (28–52)
 1037 (26–50)38 (19–65)39 (28–52)
  • Renal replacement therapy is the initiation of long-term hemodialysis or peritoneal dialysis or the receipt of a kidney transplant. The combined primary endpoint is a combination of renal replacement therapy and mortality, whichever came first. Partial remission is defined as a 50% reduction in protein-to-creatinine ratio to ≤3.5 g/10 mmol creatinine with a stable serum creatinine. Remission was considered complete when the protein-to-creatinine ratio was <0.2 g/10 mmol. Relapse is the reoccurrence of proteinuria >3.5 g/10 mmol creatinine and a 50% increase from the previous known value of proteinuria in a patient with a remission. CI, confidence interval; NA, not applicable.